- ►annals.org [PDF] JL Abrahm… - Annals of internal medicine, 1999 - Am Coll Physicians General internists often care for patients with advanced cancer. These patients have substantial
morbidity caused by moderate to severe pain and by spinal cord compres- sion. With appropriate
multidisciplinary care, pain can be controlled in 90% of patients who have advanced ... Cited by 28 - Related articles - BL Direct - All 6 versions
[CITATION] Management of Pain and Spinal Cord Compression in Patients with Advanced …
SA Fryhofer, WJ Hall, R Hornbake, CS Hunter, ME … - Ann Intern Med, 1999 Related articles
[CITATION] Management of Pain and Spinal Cord Compression in Patients with Advanced …
S ZR - Physician's Guide to End-of-life Care, 2001 - Amer College of Physicians Related articles
JL Abrahm, L Snyder - Primary Care: Clinics in Office Practice, 2001 - Elsevier Assessment and management of pain is crucial to the success of any program of care for dying
patients and their families. Pain must be controlled if dying patients are to identify and fulfill
social, psychologic, and spiritual needs; to complete life reviews; and to pass on their ... Cited by 11 - Related articles - BL Direct - All 2 versions
C Roemer-Bécuwe, A Vigano, F Romano, C … - Journal of pain and …, 2003 - Elsevier Bisphosphonates have become standard treatment in management of malignancy-induced hypercalcemia
and malignant bone pain. One obstacle to the routine use of bisphosphonates in palliative patients
is that oral bisphosphonates have low bioavailability and a degree of gastrointestinal ... Cited by 15 - Related articles - All 11 versions
B Hainline, MH Tuszynski, JB Posner - Neurology, 1992 - AAN Enterprises Nine patients presented with ataxia as the primary manifestation of epidural spinal cord
compression. Eight had known cancer, the ninth an epidural abscess. Lower-extremity
dysmetria, gait ataxia, or both, were the only neurologie signs in five patients. An incorrect ... Cited by 16 - Related articles - BL Direct - All 3 versions
JC Ruckdeschel - Seminars in oncology, 1996 - ncbi.nlm.nih.gov A multi-institutional phase II trial of paclitaxel (Taxol; Bristol-Myers Squibb Company,
Princeton, NJ) 225 mg/m2 over 3 hours and carboplatin dosed to an area under the
concentration-time curve of 6 by the Calvert formula given preoperatively every 3 weeks ... Cited by 2 - Related articles - BL Direct - All 3 versions
